CombiMatrix Corporation Granted Conditional Approval From New York State Department of Health to Market Prenatal Miscarriage Analysis Test

Published: Jun 25, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

IRVINE, Calif., June 25, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing services for developmental disorders and cancer diagnostics, today announced that its chromosomal microarray analysis (CMA) test for miscarriage analysis has received conditional approval from the New York State's Department of Health for testing on patient samples from the state. With nearly 20 million people, New York is the third most populated state in the nation, behind only California and Texas.

Help employers find you! Check out all the jobs and post your resume.

Back to news